Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.56 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.51 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577515 | 0.87 | POLB (0.53) | SIGMAR1SLC6A12TMEM97MCHR1MEN1 | |
| SCHEMBL5577726 | 0.85 | SIGMAR1 (0.51) | SIGMAR1BCHEACHEBACE1SLC6A12 | |
| SCHEMBL5577829 | 0.85 | SIGMAR1 (0.51) | SIGMAR1SLC6A12TMEM97MCHR1MEN1 | |
| SCHEMBL5577373 | 0.85 | SIGMAR1 (0.48) | SIGMAR1SLC6A12TMEM97MCHR1CHRM4 | |
| SCHEMBL5577565 | 0.85 | CCR3 (0.55) | SIGMAR1BCHEACHEBACE1SLC6A12 | |
| SCHEMBL5577399 | 0.85 | SIGMAR1 (0.53) | SIGMAR1SLC6A12TMEM97MCHR1CHRM4 | |
| SCHEMBL5577451 | 0.85 | SIGMAR1 (0.48) | SIGMAR1SLC6A12TMEM97MCHR1MEN1 | |
| SCHEMBL5577659 | 0.84 | SIGMAR1 (0.52) | SIGMAR1SLC6A12TMEM97MCHR1CHRM4 | |
| SCHEMBL5577342 | 0.84 | DRD4 (0.57) | SIGMAR1SLC6A12TMEM97MCHR1CHRM4 | |
| SCHEMBL5577906 | 0.84 | SIGMAR1 (0.48) | SIGMAR1SLC6A12TMEM97MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | SIGMAR1 3281/4885BCHE 1116/4885ACHE 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.